P61964 (WDR5_HUMAN) Homo sapiens (Human)
WD repeat-containing protein 5 UniProtKBProtein AtlasInterProSTRINGInteractive Modelling
334 aa; Sequence (Fasta) ;
71 identical sequences
It is possible new templates exist for this target since these models were created.
Available Structures
168 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| X-ray structure of WDR5 bound to the WDR5 win motif peptide |
Heteromer | 100 | 1×SO4; | |||
| Crystal structure of human WDR5 in complex with WDR5 |
Heteromer | 100 | ||||
| Cyclic peptide binder of the WBM-site of WDR5 |
Heteromer P01106; | 100 | ||||
| Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-40333 |
Heteromer Q9Y4B6; | 100 | 1×A1AM2; | |||
| Modulating Protein-Protein Interactions with Visible Light Peptide Backbone Switches |
Heteromer G2XKQ0; | 100 | 3×K; 2×NA; | |||
| WDR5 and Histone H3 Lysine 4 dimethyl complex at 2.1 angstrom |
Heteromer P68431; | 99.02 | ||||
| WD repeat containing protein 5 (WDR5)- PER2 peptide |
Heteromer O54943; P61965; | 100 | 2×144; 2×CL; 1×1PE; | |||
| WDR5 in complex with influenza NS1 C-terminal tail |
Heteromer P03495; | 100 | 17×UNX; | |||
| Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-40407 |
Heteromer Q9Y4B6; | 100 | 1×A1ANM; | |||
| Crystal structure of Nanog(R100A) in complex with Wdr5 |
Heteromer P61965; Q80Z64; | 100 | ||||
| X-ray structure of WDR5-MLL3 Win motif peptide binary complex |
Heteromer Q8NEZ4; | 100 | ||||
| Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL2 |
Heteromer O14686; | 100.0 | 1×BTB; 1×SO4; | |||
| X-ray structure of WDR5delta24 bound to the Kaposi's sarcoma herpesvirus LANA win motif peptide |
Heteromer Q9QR71; | 100.0 | ||||
| Crystal structure of the KANSL1-WDR5 complex. |
Heteromer Q7Z3B3; | 100.0 | 2×GOL; | |||
| X-ray structure of WDR5-SETd1a Win motif peptide binary complex |
Heteromer O15047; | 100 | ||||
| Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL4 |
Heteromer Q9UMN6; | 100 | ||||
| Crystal structure of WDR5 in complex with a H3Q5ser peptide |
Heteromer P68431; | 100 | 1×SRO; | |||
| Crystal structure of WDR5 in complex with H3K4me3Q5ser peptide |
Heteromer P68431; | 100 | 1×GOL; 1×EDO; 1×SRO; | |||
| Crystal structure of human WDR5 in complex with monomethyl H3R2 peptide |
Heteromer Q6NXT2; | 100 | 3×GOL; 1×SO4; | |||
| X-ray structure of WDR5-MLL1 Win motif peptide binary complex |
Heteromer Q03164; | 100 | ||||
| WDR5 in complex with histone H3Q5his peptide |
Heteromer P68431; | 100 | ||||
| Structure of WDR5 bound to MLL1 peptide |
Heteromer Q03164; | 100 | 3×SO4; | |||
| X-ray structure of WDR5-MLL4 Win motif peptide binary complex |
Heteromer Q9UMN6; | 100 | ||||
| Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1A |
Heteromer O15047; | 100 | ||||
| X-ray structure of WDR5-SETd1b Win motif peptide binary complex |
Heteromer Q9UPS6; | 100 | ||||
| Crystal structure of WDR5 in complex with MYC MbIIIb peptide |
Heteromer P01106; | 100 | 1×TRS; 1×EDO; | |||
| WDR5 in complex with unmodified H3K4 peptide |
Heteromer Q6P823; | 100 | ||||
| X-ray structure of WDR5-MLL2 Win motif peptide binary complex |
Heteromer O14686; | 100 | ||||
| WDR5 in complex with trimethylated H3K4 peptide |
Heteromer Q6P823; | 100 | ||||
| Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-40792 |
Heteromer Q9Y4B6; | 100 | 1×A1ANN; | |||
| WDR5 in complex with monomethylated H3K4 peptide |
Heteromer Q6P823; | 100 | ||||
| Crystal structure of the KANSL1-WDR5-KANSL2 complex. |
Heteromer Q7Z3B3; Q9H9L4; | 100 | ||||
| Crystal structure of the ternary complex of DCAF1 and WDR5 with PROTAC, OICR-41114 |
Heteromer Q9Y4B6; | 100 | 1×A1BAF; | |||
| Crystal structure of WDR5 in complex with the WDR5-interacting motif of MLL3 |
Heteromer Q8NEZ4; | 100.0 | ||||
| Crystal structure of WDR5 in complex with the WDR5-interacting motif of SET1B |
Heteromer Q9UPS6; | 100.0 | ||||
| WDR5 and unmodified Histone H3 complex at 2.25 Angstrom |
Heteromer P68431; | 98.68 | ||||
| Structural and biochemical insights into MLL1 core complex assembly and regulation. |
Heteromer Q03164; Q15291; | 100 | ||||
| WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE RECRUITED TO NOVEL SITE |
Heteromer P61965; Q8BX09; | 100 | 2×GOL; | |||
| Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer |
Heteromer P40337; Q15369; Q15370; | 100 | 1×8KH; | |||
| Crystal structure of WDR5-Mb(S4) monobody complex |
Heteromer | 100 | ||||
| Crystal structure of the binary complex of DCAF1 and WDR5 |
Heteromer Q9Y4B6; | 100 | 1×IMD; | |||
| Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… |
Heteromer P40337; Q15369; Q15370; | 100 | 4×SCN; 5×EDO; 1×VKA; 1×GOL; 1×NA; | |||
| Symmetric Dimethylation of H3 Arginine 2 is a Novel Histone Mark that Supports Euchromatin Maintena… |
Heteromer P68431; | 100 | ||||
| Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… |
Heteromer P40337; Q15369; Q15370; | 100 | 1×GOL; 1×X6M; | |||
| Structure of WDR5 in complex with WIN motif containing SET1B |
Heteromer Q9UPS6; | 100.0 | ||||
| WDR5 IN COMPLEX WITH AN RBBP5 PEPTIDE AND HISTONE H3 PEPTIDE |
Heteromer P61965; P68433; Q8BX09; | 100 | 2×GOL; | |||
| Crystal structure of WDR5 in complex with the WIN peptide of PDPK1 |
Heteromer O15530; | 100.0 | ||||
| Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100 | ||||
| Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100.0 | ||||
| Cryo-EM structure of MLL1 in complex with RbBP5, WDR5, SET1, and ASH2L bound to the nucleosome (Cla… |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100 | ||||
| Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode02 |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100 | ||||
| Cryo-EM structure of MLL1 core complex bound to the nucleosome |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9C005; Q9UBL3; | 100 | 2×SAH; 2×ZN; | |||
| Cryo-EM structure of MLL1 in complex with RbBP5 and WDR5 bound to the nucleosome |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; | 100 | 1×SAH; 1×ZN; | |||
| Complex between MLL1-WRAD and an H2B-ubiquitinated nucleosome |
Heteromer B4DIJ7; P02281; P06897; P0CG47; P62799; P84233; Q15291; Q9C005; Q9UBL3; | 100 | 1×SAH; 1×ZN; | |||
| Complex between RbBP5-WDR5 and an H2B-ubiquitinated nucleosome |
Heteromer P02281; P02302; P06897; P0CG47; P62799; Q15291; | 100 | ||||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1) |
Heteromer P40337; Q15369; Q15370; | 100.0 | 15×SCN; 13×EDO; 1×P6G; 1×Q3X; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2) |
Heteromer P40337; Q15369; Q15370; | 100 | 5×SCN; 1×Q3X; 7×EDO; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker |
Heteromer P40337; Q15369; Q15370; | 100.0 | 1×Q3R; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker |
Heteromer P40337; Q15369; Q15370; | 100 | 10×SCN; 1×Q43; 4×EDO; 1×K; | |||
| Structural basis of WDR5-MLL interaction |
Heteromer Q03164; | 100 | 2×SO4; | |||
| Cryo-EM structure of MLL1-NCP (H3K4M) complex, mode01 |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100 | ||||
| Cryo-EM structure of human MLL1-ubNCP complex (3.2 angstrom) |
Heteromer P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3; | 100 | 1×SAH; 1×ZN; 1×LYS; 1×GLN; | |||
| Cryo-EM structure of human MLL1-ubNCP complex (4.0 angstrom) |
Heteromer P02281; P06897; P62799; P62979; P84233; Q03164; Q15291; Q9UBL3; | 100 | 1×SAH; 1×ZN; | |||
| Cryo-EM structure of human MLL3-ubNCP complex (4.0 angstrom) |
Heteromer P02281; P06897; P62799; P62979; P84233; Q15291; Q8NEZ4; Q9UBL3; | 100 | 1×ZN; | |||
| Cryo-EM structure of human MLL1-NCP complex, binding mode1 |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100 | 1×SAH; 1×ZN; 1×LYS; 1×GLN; | |||
| Cryo-EM structure of human MLL1-NCP complex, binding mode2 |
Heteromer P02281; P06897; P62799; P84233; Q03164; Q15291; Q9UBL3; | 100 | 1×SAH; 1×ZN; | |||
| Crystal structure of human WD repeat-containing protein 5 in complex with 4-(3,5-dimethoxybenzyl)-9… | homo-2-mer | 100.0 | 2×VV3; | |||
| Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera… | homo-2-mer | 100 | 2×QF1; | |||
| Characterization of Peptide Ligands Against WDR5 Isolated Using Phage Display Technique | homo-2-mer | 100.0 | ||||
| WDR5 covalently modified at Y228 by (R)-2-SF | homo-2-mer | 100 | 2×XKN; 4×GOL; 2×SO4; 2×CL; | |||
| Structure of wdr5 | monomer | 100.0 | 1×CL; | |||
| Crystal structure of human WDR5 in complex with (1M)-N-[(3,5-difluoro[1,1'-biphenyl]-4-yl)methyl]-6… | monomer | 100.0 | 1×YJR; | |||
| Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter… | monomer | 100 | 1×QBS; 2×SO4; | |||
| Structure of the cryo-trapped WDR5:CS-VIP8 cocrystal after illumination at 405 nm and 180 K | monomer | 100 | ||||
| Structure of WDR5:CS-VIP8 cocrystal after illumination in situ | monomer | 100 | ||||
| Structural characterisation of WDR5:CS-VIP8 interaction in cis state 1 | monomer | 100 | ||||
| Structure of WDR5:CS-VIP8 crystal after illumination at 405 nm and room temperature | monomer | 100.0 | ||||
| Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dih… | monomer | 100.0 | 1×Q41; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100.0 | 1×Q0Y; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100.0 | 1×Q1M; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100.0 | 1×Q1J; | |||
| Crystal structure of human WDR5 in complex with compound 9e | monomer | 100.0 | 1×5MO; 1×GOL; 1×CL; 5×EDO; 14×UNX; | |||
| WDR5delta23 | monomer | 100 | 2×SO4; | |||
| Crystal structure of human WD repeat domain 5 with compound MM-401 | monomer | 100.0 | ||||
| Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity | monomer | 100 | 1×HLP; | |||
| Crystal structure of human WDR5 in complex with PTEN | monomer | 100 | ||||
| Crystal structure of human WD repeat domain 5 with compound MM-402 | monomer | 100 | ||||
| WD repeat-containing protein 5 complexed with 4-(7-((1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(triflu… | monomer | 100 | 1×BEN; 1×UY9; | |||
| Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter… | monomer | 100 | 2×QBM; | |||
| Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin… | monomer | 100 | 2×DMS; 2×G2V; | |||
| Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-me… | monomer | 100 | 1×IA9; 2×EDO; 24×UNX; | |||
| Discovery of fragment-inspired heterocyclic benzenesulfonamides as inhibitors of the WDR5-MYC inter… | monomer | 100 | 1×QBP; | |||
| Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin… | monomer | 100 | 1×G2D; | |||
| Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin… | monomer | 100 | 1×NA; 1×FZM; | |||
| Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex | monomer | 100 | ||||
| WDR5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1H-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluor… | monomer | 100 | 1×BEN; 1×M4U; | |||
| WDR5 in complex with a WIN site inhibitor | monomer | 100 | 1×HHM; 1×SO4; 2×DMS; | |||
| Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei… | monomer | 100 | ||||
| WDR5 in complex with Myc site fragment inhibitor | monomer | 100.0 | 1×Q8D; | |||
| WDR5 in complex with Myc site fragment inhibitor | monomer | 100.0 | 1×Q8G; | |||
| Crystal structure of human WDR5 in complex with compound 19 | monomer | 100 | 1×6IQ; 4×GOL; 4×EDO; | |||
| Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex | monomer | 100 | ||||
| Crystal structure of human WDR5 in complex with compound OICR-9429 | monomer | 100 | 1×35Q; 1×UNX; | |||
| Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera… | monomer | 100.0 | 1×Q8S; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100 | 1×Q0M; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100 | 1×Q1P; 1×Q1S; | |||
| Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin… | monomer | 100 | 1×G1Y; 1×DMS; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100 | 1×Q1G; | |||
| Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity | monomer | 100 | 1×HLS; 1×SO4; | |||
| WDR5 bound to inhibitor MM-589 | monomer | 100 | 1×9BA; 1×SO4; 7×EDO; | |||
| WDR5delta23 bound to (2-(3-phenylpropyl)-1H-imidazol-4-yl)methanol | monomer | 100.0 | 1×OGY; 1×CL; | |||
| WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acetamide | monomer | 100.0 | 1×SO4; 1×OH7; 1×CL; | |||
| Crystal structure of human WDR5 in complex with monomethyl L-arginine | monomer | 100 | 1×SO4; 2×GOL; 1×NMM; | |||
| Crystal structure of human WDR5 in complex with symmetric dimethyl-L-arginine | monomer | 100 | 3×SO4; 3×GOL; 1×2MR; | |||
| Crystal structure of human WDR5 in complex with MR4397 | monomer | 100 | 1×ZHF; 3×EDO; 1×UNX; | |||
| Crystal structure of the human WDR5 in complex with LH168 compound | monomer | 100.0 | 1×A1A16; 2×EDO; | |||
| WDR5delta23 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)benzamide | monomer | 100 | 1×OH1; | |||
| Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex | monomer | 100 | ||||
| Crystal structure of WDR5, WD repeat domain 5 in complex with compound SGC-DS-MT-0345 | monomer | 100 | 1×37F; 1×CL; 3×EDO; 7×UNX; | |||
| Crystal structure of human WDR5 in complex with compound 9h | monomer | 100 | 1×5ML; 1×GOL; 1×CL; 8×EDO; 13×UNX; | |||
| Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the WDR5:MYC protei… | monomer | 100.0 | 1×Q0S; | |||
| Crystal structure of human WDR5 in complex with compound 9o | monomer | 100 | 1×5MN; 1×EDO; 11×UNX; | |||
| Crystal structure of human WDR5 in complex with compound 9d | monomer | 100.0 | 1×5MQ; 9×EDO; 2×UNX; | |||
| Crystal structure of human WD repeat domain 5 with compound | monomer | 100.0 | 1×0BW; 2×EDO; 4×CL; 2×SO4; 17×UNX; | |||
| Crystal structure of human WDR5 in complex with N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-… | monomer | 100 | 1×YJN; | |||
| Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-… | monomer | 100.0 | 1×MBU; | |||
| Crystal structure of human WD repeat domain 5 with compound | monomer | 100.0 | 1×NP7; 8×EDO; 7×UNX; | |||
| Structure of WDR5 in complex with WIN motif containing MBD3C R45E/V46G | monomer | 100 | ||||
| Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex | monomer | 100 | ||||
| WDR5 in Complex with Dimethylated H3K4 Peptide | monomer | 100 | ||||
| Structure of WDR5 in complex with WIN motif containing MBD3C | monomer | 100.0 | ||||
| WDR5 in complex with a WIN site inhibitor | monomer | 100 | 1×HH7; 1×DMS; 1×SO4; | |||
| Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protei… | monomer | 100 | ||||
| Crystal structure of human WDR5 in complex with L-arginine | monomer | 100 | 1×ARG; 2×SO4; 4×GOL; | |||
| WDR5 in complex with MLL Win motif peptidomimetic | monomer | 100 | ||||
| WDR5delta23 bound to (2-butyl-1H-imidazol-4-yl)methanol | monomer | 100.0 | 1×OHJ; | |||
| Crystal structure of WDR5 mutant (S62A) | monomer | 99.67 | ||||
| Structure of WDR5 in complex with WIN motif containing MBD3C F47A | monomer | 100 | ||||
| Crystal structure of WDR5 mutant (W330F) | monomer | 99.67 | ||||
| Structure of WDR5 in complex with WIN motif containing MBD3C C44S/R45E/V46G | monomer | 100 | ||||
| Structural characterisation of WDR5:CS-VIP8 interaction in cis state 2 | monomer | 100 | ||||
| Crystal structure of WDR5 mutant (W330Y) | monomer | 99.67 | ||||
| Crystal structure of human WD repeat domain 5 with compound MM-102 | monomer | 100.0 | ||||
| Crystal structure of human WD repeat domain 5 with compound MM-101 | monomer | 100 | ||||
| Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin… | monomer | 100.0 | 1×HLM; | |||
| Crystal of WDR5 (apo-form) | monomer | 100 | ||||
| WDR5delta32 bound to peptidomimetic | monomer | 100 | 1×OK4; 3×SO4; | |||
| WDR5delta32 bound to N-(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)acrylamide | monomer | 100 | 1×OJP; 3×SO4; | |||
| Crystal structure of WDR5/histone H3 complex | monomer | 100 | ||||
| Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera… | monomer | 100 | 1×Q8M; | |||
| WDR5delta32 bound to (2-methyl-1H-imidazol-4-yl)methanol | monomer | 100 | 1×OHG; 3×SO4; | |||
| Discovery of fragment-inspired heterocyclic benzenesulfonmides as inhibitors of the WDR5-MYC intera… | monomer | 100.0 | 1×Q8P; | |||
| Displacement of WDR5 from chromatin by a pharmacological WIN site inhibitor with picomolar affinity | monomer | 100.0 | 1×HLJ; | |||
| Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3 based peptide mimetic | monomer | 100.0 | ||||
| WDR5delta32 bound to N-(4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)-2-phenylacetamide | monomer | 100 | 1×OJG; 3×SO4; | |||
| WDR5delta32 bound to ethyl 3-(4-(hydroxymethyl)-1H-imidazol-2-yl)propanoate | monomer | 100 | 1×OJM; 2×SO4; 1×EDO; | |||
| WDR5delta32 bound to methyl benzyl(4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate | monomer | 100 | 2×SO4; 1×OJJ; | |||
| Crystal structure of human WDR5 | monomer | 100 | ||||
| WDR5delta32 bound to benzyl (4-(5-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate | monomer | 100 | 1×OHV; 3×SO4; | |||
| WD repeat-containing protein 5 complexed with N-[(3,5-dimethoxyphenyl)methyl]-4'-fluoro-5-{[(2E)-2-… | monomer | 99.67 | 1×Q6S; | |||
| Structure of WDR5 in complex with WIN motif containing SET1B E1750R/G1751V | monomer | 100 | ||||
| Crystal structure of human WDR5 in complex with compound WM662 | monomer | 100 | 1×X8N; 4×GOL; 1×SO4; 1×PGE; | |||
| WDR5delta32 bound to (2-(3-methoxy-3-phenylpropyl)-1H-imidazol-4-yl)methanol | monomer | 100 | 1×OH4; 1×PEG; | |||
| WDR5delta32 bound to methyl (4-(4-(hydroxymethyl)-1H-imidazol-2-yl)butyl)carbamate | monomer | 100 | 1×OGM; 1×SO4; | |||
| WD repeat containing protein 5 (WDR5)- N225A mutant | monomer | 99.67 | ||||
| Discovery of Potent 2-Aryl-6,7-Dihydro-5HPyrrolo[ 1,2-a]imidazoles as WDR5 WIN-site Inhibitors Usin… | monomer | 100 | 1×G2J; 2×SO4; 2×DMS; | |||
| Modulation of MLL1 Methyltransferase Activity | monomer | 100 | 1×7DC; | |||
| Modulation of MLL1 Methyltransferase Activity | monomer | 100 | 1×7DU; | |||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 2gnq.1.A | monomer | 0.92 | 100.00 | |||
| 9j5v.1.A | monomer | 0.70 | 24.46 | |||
| 9j5v.1.A | monomer | 0.70 | 24.46 | |||